1-2 of 2
Ana Alarcon Tomas, MD
Close
Sort by
Journal Articles

Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas

Brandon S. Imber, MD MA, Miguel-Angel Perales, MD, Jessica Flynn, BS, Josel D Ruiz, MPH, Sean Devlin, PhD, Ana Alarcon Tomas, MD, Carla Hajj, MD, Connie Lee Batlevi, MDPhD, Parastoo B. Dahi, MD, Richard J Lin, MDPhD, Jae H. Park, MD, Michael Scordo, MD, Gunjan L. Shah, MDMS, Sergio A. Giralt, MD, Craig S. Sauter, MD, M. Lia Palomba, MD, Joachim Yahalom, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-140991
Published: 2020
Journal Articles

Pre-Transplant Fecal Microbial Diversity Independently Predicts Critical Illness after Hematopoietic Cell Transplantation

Fatima I. Adhi, MD, Eric R. Littmann, BA, Ying Taur, MD MPH, Molly A. Maloy, MS, Kate A Markey, PhDMBBS,FRACP, Emily Fontana, BA, Luigi A Amoretti, B.S., Roberta Wright, M.S., M.B.S., Miriam Sanchez-Escamilla, MD, Nerea Castillo Flores, MD PhD, Ana Alarcon Tomas, MD, Richard J Lin, MD PhD, Lucrecia Yáñez, MD PhD, Daniel Brereton, B.A., Annelie Clurman, BA, John B. Slingerland, BSc, Gunjan L. Shah, MD, Christina Cho, MD, Michael Scordo, MD, Ioannis Politikos, MD, Boglarka Gyurkocza, MD, Doris M Ponce, MD, Juliet Barker, MBBS, Miguel-Angel Perales, MD, Sergio A Giralt, MD, Marcel R.M. van den Brink, MD PhD, Eric G. Pamer, MD, Jonathan U. Peled, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3264.
https://doi.org/10.1182/blood-2019-124902
Published: 2019